AR061346A1 - Pirazolopiridinas sustituidas y sus sales composiciones farmaceuticas que las comprenden metodos para prepararlas y sus usos - Google Patents
Pirazolopiridinas sustituidas y sus sales composiciones farmaceuticas que las comprenden metodos para prepararlas y sus usosInfo
- Publication number
- AR061346A1 AR061346A1 ARP070102552A ARP070102552A AR061346A1 AR 061346 A1 AR061346 A1 AR 061346A1 AR P070102552 A ARP070102552 A AR P070102552A AR P070102552 A ARP070102552 A AR P070102552A AR 061346 A1 AR061346 A1 AR 061346A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- heterocycloalkyl
- cycloalkyl
- nra
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 11
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 230000002074 deregulated effect Effects 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- -1 hydroxy, amino Chemical group 0.000 abstract 2
- 150000005229 pyrazolopyridines Chemical class 0.000 abstract 2
- 230000006444 vascular growth Effects 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 abstract 1
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 abstract 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06090109A EP1867648A1 (en) | 2006-06-13 | 2006-06-13 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. |
| EP07090020 | 2007-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061346A1 true AR061346A1 (es) | 2008-08-20 |
Family
ID=38445661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102552A AR061346A1 (es) | 2006-06-13 | 2007-06-12 | Pirazolopiridinas sustituidas y sus sales composiciones farmaceuticas que las comprenden metodos para prepararlas y sus usos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7846928B2 (enExample) |
| EP (1) | EP2061790B1 (enExample) |
| JP (1) | JP5475442B2 (enExample) |
| KR (1) | KR20090018212A (enExample) |
| AR (1) | AR061346A1 (enExample) |
| AU (1) | AU2007260216A1 (enExample) |
| BR (1) | BRPI0711961A2 (enExample) |
| CA (1) | CA2654789C (enExample) |
| CL (1) | CL2007001711A1 (enExample) |
| CR (1) | CR10505A (enExample) |
| EA (1) | EA200802407A1 (enExample) |
| EC (1) | ECSP088963A (enExample) |
| ES (1) | ES2515117T3 (enExample) |
| GT (1) | GT200800285A (enExample) |
| IL (1) | IL195813A0 (enExample) |
| MX (1) | MX2008015955A (enExample) |
| NO (1) | NO20090171L (enExample) |
| PE (1) | PE20080205A1 (enExample) |
| TW (1) | TW200815438A (enExample) |
| UY (1) | UY30409A1 (enExample) |
| WO (1) | WO2007144204A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| KR20100093552A (ko) | 2007-11-02 | 2010-08-25 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 ｃ-세타로서의 [1ｈ-피라졸로[3,4-ｂ]피리딘-4-일]-페닐 또는 -피리딘-2-일 유도체 |
| CA2722606A1 (en) * | 2008-05-05 | 2009-11-12 | Amgen Inc. | Urea compounds as gamma secretase modulators |
| EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| JP5689069B2 (ja) | 2008-11-20 | 2015-03-25 | ジェネンテック， インコーポレイテッド | ピラゾロピリジンｐｉ３ｋ阻害剤化合物及び使用方法 |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| WO2011076744A1 (en) | 2009-12-21 | 2011-06-30 | Novartis Ag | Disubstituted heteroaryl-fused pyridines |
| WO2013148460A1 (en) * | 2012-03-26 | 2013-10-03 | Swenson Rolf E | Novel sphingosine 1-phosphate receptor antagonists |
| US20150164910A1 (en) * | 2012-06-15 | 2015-06-18 | The Regents Of The University Of Califonia | Antiviral compounds and methods of use |
| US11059817B2 (en) | 2015-09-23 | 2021-07-13 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CA3072362A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| SG11202011299PA (en) | 2018-05-17 | 2020-12-30 | Forma Therapeutics Inc | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| MY209034A (en) | 2018-10-05 | 2025-06-17 | Forma Therapeutics Inc | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
| TW202136238A (zh) * | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | RORγt抑制劑及其製備方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670364B2 (en) * | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| JP2007515474A (ja) * | 2003-12-22 | 2007-06-14 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法 |
| FR2876691B1 (fr) * | 2004-10-18 | 2006-12-29 | Sanofi Aventis Sa | Derives de pyridine, leur preparation, leur application en therapeutique |
| MX2007005120A (es) * | 2004-10-29 | 2007-07-16 | Abbott Lab | Nuevos inhibidores de cinasa. |
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| EP1683796A1 (en) * | 2005-01-24 | 2006-07-26 | Schering Aktiengesellschaft | Pyrazolopyridines, their preparation and their medical use |
| RS50821B (sr) * | 2005-06-27 | 2010-08-31 | Sanofi-Aventis | Derivati pirazolopiridina kao inhibitori beta-adrenergičnog receptora kinaze 1 |
-
2007
- 2007-06-11 TW TW096121006A patent/TW200815438A/zh unknown
- 2007-06-12 JP JP2009514716A patent/JP5475442B2/ja not_active Expired - Fee Related
- 2007-06-12 EP EP07764753.5A patent/EP2061790B1/en active Active
- 2007-06-12 EA EA200802407A patent/EA200802407A1/ru unknown
- 2007-06-12 US US11/761,672 patent/US7846928B2/en not_active Expired - Fee Related
- 2007-06-12 ES ES07764753.5T patent/ES2515117T3/es active Active
- 2007-06-12 BR BRPI0711961-5A patent/BRPI0711961A2/pt not_active IP Right Cessation
- 2007-06-12 PE PE2007000741A patent/PE20080205A1/es not_active Application Discontinuation
- 2007-06-12 UY UY30409A patent/UY30409A1/es not_active Application Discontinuation
- 2007-06-12 MX MX2008015955A patent/MX2008015955A/es not_active Application Discontinuation
- 2007-06-12 KR KR1020097000562A patent/KR20090018212A/ko not_active Withdrawn
- 2007-06-12 AR ARP070102552A patent/AR061346A1/es unknown
- 2007-06-12 CA CA2654789A patent/CA2654789C/en not_active Expired - Fee Related
- 2007-06-12 AU AU2007260216A patent/AU2007260216A1/en not_active Abandoned
- 2007-06-12 CL CL2007001711A patent/CL2007001711A1/es unknown
- 2007-06-12 WO PCT/EP2007/005432 patent/WO2007144204A1/en not_active Ceased
-
2008
- 2008-12-09 IL IL195813A patent/IL195813A0/en unknown
- 2008-12-12 EC EC2008008963A patent/ECSP088963A/es unknown
- 2008-12-12 GT GT200800285A patent/GT200800285A/es unknown
- 2008-12-12 CR CR10505A patent/CR10505A/es not_active Application Discontinuation
-
2009
- 2009-01-12 NO NO20090171A patent/NO20090171L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2654789C (en) | 2014-08-05 |
| CL2007001711A1 (es) | 2008-01-04 |
| EP2061790A1 (en) | 2009-05-27 |
| AU2007260216A1 (en) | 2007-12-21 |
| KR20090018212A (ko) | 2009-02-19 |
| GT200800285A (es) | 2009-03-09 |
| EP2061790B1 (en) | 2014-08-13 |
| NO20090171L (no) | 2009-03-12 |
| EA200802407A1 (ru) | 2009-06-30 |
| JP5475442B2 (ja) | 2014-04-16 |
| CR10505A (es) | 2009-03-20 |
| MX2008015955A (es) | 2009-01-09 |
| IL195813A0 (en) | 2009-09-22 |
| CA2654789A1 (en) | 2007-12-21 |
| JP2009539914A (ja) | 2009-11-19 |
| ES2515117T3 (es) | 2014-10-29 |
| ECSP088963A (es) | 2009-01-30 |
| WO2007144204A1 (en) | 2007-12-21 |
| BRPI0711961A2 (pt) | 2012-01-17 |
| US20080058326A1 (en) | 2008-03-06 |
| US7846928B2 (en) | 2010-12-07 |
| UY30409A1 (es) | 2008-01-31 |
| PE20080205A1 (es) | 2008-06-01 |
| TW200815438A (en) | 2008-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061346A1 (es) | Pirazolopiridinas sustituidas y sus sales composiciones farmaceuticas que las comprenden metodos para prepararlas y sus usos | |
| AR061345A1 (es) | Aminopirazolopiridinas sustituidas y sus sales, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos en el tratamiento de enfermedades de crecimiento vascular desregulado. | |
| AR064348A1 (es) | 3-h-pirazolopiridinas y sales de estas, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos | |
| AR078535A1 (es) | Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR100691A1 (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
| AR086319A1 (es) | Compuestos heterociclicos fusionados como moduladores de canal ionico | |
| AR088886A1 (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii | |
| AR061643A1 (es) | Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1. | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| AR043998A1 (es) | Acidos fenoxiaceticos | |
| AR056863A1 (es) | Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas, metodos de preparacion y usos de los mismos | |
| CL2009000127A1 (es) | Compuestos derivados de [indol, azaindol]-2-carboxamida sustituidos con un grupo silanilo; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento del dolor, inflamacion, trastornos metabolicos, entre otras enfermedades mediadas por la modulacion del receptor trpv1. | |
| AR069509A1 (es) | Pirido (3,2-e) pirazinas, su procedimiento de preparacion y uso como inhibidores de fosfodiesterasa 10 | |
| AR085750A1 (es) | Derivados de pirazolo-pirimidina | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR055202A1 (es) | Derivados de imidazolcarboxamida como inhibidores de fructosa -1,6- biofosfatasa y composiciones farmaceuticas que los contienen | |
| AR078623A1 (es) | Compuestos herbicidas | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| AR114175A1 (es) | Derivados de fenilpiridazinonas como compuestos herbicidas | |
| AR103088A1 (es) | Compuestos herbicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |